Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Triumvira Immunologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11089
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Triumvira Immunologics Inc (Triumvira) is a biopharmaceutical company developing engineered T cell therapies for the treatment of multiple cancers. Its proprietary immuno-oncology platform T cell Antigen Coupler (TAC), enables natural T cell receptor to induce a controlled, tumor-specific response with reduced toxicities and thus eliminates solid tumors. The company’s lead product candidate CD19-TAC01, is targeted for the treatment of CD19 positive B-cell malignancies such as Diffuse Large B Cell Lymphoma (DLBCL). Triumvira seeks to work in partnership with other pharmaceutical companies for collaboration and licensing opportunities of its TAC technology platform. The company has operations with research facilities in Hamilton, Canada. Triumvira is headquartered in Austin, Texas, the US.

Triumvira Immunologics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Triumvira Immunologics Raises USD1.4 Million in Seed Financing Round 10
Licensing Agreements 11
Centre for Commercialization of Cancer Immunotherapy Enters into Licensing Agreement with Triumvira Immunologics 11
Triumvira Immunologics Enters into Licensing Agreement with McMaster University 12
Triumvira Immunologics Inc – Key Competitors 13
Triumvira Immunologics Inc – Key Employees 14
Triumvira Immunologics Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Corporate Communications 16
Jun 25, 2018: Triumvira Immunologics Names Scott Smith As Board Director 16
Jun 11, 2018: Triumvira Names Donna Rill As Chief Technology Officer 17
Apr 05, 2018: Triumvira Immunologics Appoints Cynthia Collins to Board of Directors 18
Jan 04, 2018: Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer 19
Product News 20
Aug 03, 2018: Nature Communications publishes studies comparing Triumvira’s T cell antigen coupler (TAC) technology with CAR T cell therapy 20
04/30/2018: Triumvira Immunologics to Present at Two Upcoming Conferences: International Society for Cellular Therapy and Bloom Burton & Co. Healthcare Investor Conference 21
03/22/2018: Triumvira Immunologics to Present at the 25th BioCentury Future Leaders Conference 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Triumvira Immunologics Raises USD1.4 Million in Seed Financing Round 10
Centre for Commercialization of Cancer Immunotherapy Enters into Licensing Agreement with Triumvira Immunologics 11
Triumvira Immunologics Enters into Licensing Agreement with McMaster University 12
Triumvira Immunologics Inc, Key Competitors 13
Triumvira Immunologics Inc, Key Employees 14
Triumvira Immunologics Inc, Other Locations 15

List of Figures
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Volkswind GmbH:電力:M&Aディール及び事業提携情報
    Summary Volkswind GmbH (Volkswind) a subsidiary of Axpo Holding AG, is an independent renewable power producer. It undertakes the planning, development, construction and operations of wind power plants. Volkswind builds wind farms with wind turbines from various suppliers including Seimens, Enercon, …
  • The Home Depot, Inc.:企業のM&A・事業提携・投資動向
    The Home Depot, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Home Depot, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Blackline Safety Corp. (BLN):企業の財務・戦略的SWOT分析
    Blackline Safety Corp. (BLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Hydrogenics Corporation (HYG)-エネルギー分野:企業M&A・提携分析
    Summary Hydrogenics Corporation (Hydrogenics) is a provider of power generation equipment. It designs, develops, and manufactures hydrogen generation, energy storage, and fuel cell products. The company produces products on water electrolysis technology and proton exchange membrane (PEM) technology. …
  • DTE Energy Co (DTE)-エネルギー分野:企業M&A・提携分析
    Summary DTE Energy Company (DTE Energy) is a diversified energy company that develops and manages energy-related businesses and services. It has presence in the electricity value chain from generation, procurement, to transmission, distribution, and sales. The company procures, stores, and transport …
  • Cubic Corp (CUB):企業の財務・戦略的SWOT分析
    Cubic Corp (CUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Royal Mail plc:企業の戦略・SWOT・財務分析
    Royal Mail plc - Strategy, SWOT and Corporate Finance Report Summary Royal Mail plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報
    Summary Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhe …
  • BearingPoint:企業の戦略的SWOT分析
    BearingPoint - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Societe Generale S.A.:企業の戦略・SWOT・財務情報
    Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report Summary Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Exide Technologies
    Exide Technologies - Strategy, SWOT and Corporate Finance Report Summary Exide Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • L’Oreal USA Inc:企業の戦略的SWOT分析
    L'Oreal USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • WesternZagros Resources Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary WesternZagros Resources ULC (WesternZagros), formerly WesternZagros Resources Ltd, a subsidiary of Crest Energy International Ltd, is an oil and gas company that acquires, develops, explores and produces crude oil and natural gas. The company holds production sharing contracts with the Kurdi …
  • S-Oil Corporation Inc (010950)-石油・ガス分野:企業M&A・提携分析
    Summary S-Oil Corporation Inc (S-Oil) is a service driven company that operates in the petroleum and petrochemical industry. The company imports and exports crude oil; as well as manufactures and sells oil refining products, petrochemical products and lube products. S-Oil also produces a wide range …
  • PT. SOHO Industri Pharmasi:製薬・医療:M&Aディール及び事業提携情報
    Summary PT. SOHO Industri Pharmasi (PT SOHO), a subsidiary of SOHO Global Health, is a pharmaceutical company that offers ethical, consumer health, herbal medicine and natural products. The company’s products include analgesic, anti-inflammatory, antipyretic, antibiotics, antifungal, antihistamine a …
  • China Sunshine Paper Holdings Company Limited:戦略・SWOT・企業財務分析
    China Sunshine Paper Holdings Company Limited - Strategy, SWOT and Corporate Finance Report Summary China Sunshine Paper Holdings Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • CAT Telecom Public Co Ltd:企業の戦略的SWOT分析
    CAT Telecom Public Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Integra LifeSciences Holdings Corp (IART):企業の財務・戦略的SWOT分析
    Integra LifeSciences Holdings Corp (IART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Crescendo Bioscience Inc-医療機器分野:企業M&A・提携分析
    Summary Crescendo Bioscience Inc (Crescendo), a subsidiary of Myriad Genetics Inc is a molecular diagnostics company that concentrates on rheumatology. The company develops quantitative, objective, and biology based tests for rheumatologists. Its vectra DA is an advanced blood test for rheumatoid ar …
  • RigNet Inc (RNET):企業の財務・戦略的SWOT分析
    RigNet Inc (RNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆